Polansky M, et al. - A sum of 20 subjects receiving at least 1 dose of rituximab therapy, either as initial therapy for severe Bullous pemphigoid (BP) or recalcitrant disease having failed conventional immunotherapies were analyzed to study the clinical consequences of candidates with BP managed with rituximab therapy. They recorded that 75% of subjects achieved remission an average of 169 days following rituximab therapy. No rituximab related deaths were reported with significantly fewer adverse events following rituximab therapy. They demonstrated steroid-sparing activity and an acceptable safety profile with the use of rituximab therapy in cases with severe BP or disease refractory to conventional therapies.